Four different BCR::ABL1 TKIs have been combinedwith chemotherapy in prospective studies of patients with Ph-positive ALL: thefirst-generation TKI imatinib, the second-generation TKIs dasatinib and nilotinib,and the third-generation TKI ponatinib. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.